The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction

Exclusion Criteria

• •allergic to basic drug
• •with progressive stroke, transient ischemia attach, cerebral infarction with posterior cerebral hemorrhage, and cerebral arteritis.
• •tumor, injury, and parasites caused cerebral embolism
• •rheumatic heart disease, coronary heart disease, and other atrial fibrillation combined heart disease caused cerebral embolism
• •subject is processing thrombolytic therapy
• •subject is pregnancy and of childbearing potential or breast feeding
• •participate in any other clinical trial in last 3 months
• •bleeding tendency patient; severe bleeding tendency in last 3 month
• •with gastric duodenal ulcer
• •participants with severe liver and kidney, hematopoietic, and metabolic diseases; Or with liver and kidney function examination abnormal
• •participants are intolerance with Aspirin Enteric-coated Tablets, or need other antiplatelet drugs
• •participants: alcoholism, drug addicted, or other situations may complicated the results
• •under other therapy that possibly influence MSC security or efficacy
• •investigator supposes not suitable to participate this clinical trail